+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of fenofibrate on lipids lipoproteins and apolipoproteins in 33 subjects with primary hypercholesterolemia



Effects of fenofibrate on lipids lipoproteins and apolipoproteins in 33 subjects with primary hypercholesterolemia



Atherosclerosis 63(1): 57-64



The effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia were assessed in a 6-month parallel group study, placebo (n=15) versus fenofibrate 300 mg/day (n=18), followed by an open label 6-month treatment period. After stabilization on an isocaloric low fat (<35% total calories) diet with <250 mg cholesterol/day and a P/S ratio of 1, and maintenance of LDL-cholesterol (LDL-C) levels .gtoreq. 175 mg/dl, subjects received placebo for 6 weeks and were then randomized into placebo or fenofibrate groups for 6 months, followed by open label treatment for 6 months. During the 6-month double-blind period, compared to the placebo group, the treatment group had significant reductions in total cholesterol, LDL-C, total apo B, and triglyceride, and increments in HDL-cholesterol, apolipoprotein A-I and apolipoprotien A-II (P < 0.01 for all comparisons). Compared to placebo baseline, therapy with fenofibrate resulted in a reduction of LDL-C, apo B, and the LDL-C/HDL-C ratio of 15%, 13%, and 18% respectively; HDL-C, Apo A-I, and apo A-II increased respectively 12%, 13% and 30% (P < 0.01 for all comparisons). Mean adherence during the double blind phase of the trial was 95% in the drug group and 96% in the placebo group. An additional 6 months of open label fenofibrate therapy maintained the reduced total and LDL-C as well as the elevated HDL-C, apo A-I and apo A-II in the drug-drug group. Similar lipid, lipoprotein, and apolipoprotein changes were achieved in the placebo-drug group, so that the two sequence groups did not differ at the end of 6 months of open label therapy, P > 0.1. In subjects with primary hypercholesterolemia, fenofibrate, in conjunction with diet, effectively lowered LDL-C, apo B, and triglycerides, and increased HDL-C, apo A-I, and apo A-II. These effects, combined with its ease of administration and lack of side effects, enhance fenofibrate's importance and utility as a pharmacologic agent in the treatment of hypercholesterolemic subjects.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 005304062

Download citation: RISBibTeXText

PMID: 3548734

DOI: 10.1016/0021-9150(87)90082-7


Related references

Effect of fenofibrate on lipids lipoproteins and apolipoproteins in primary hypercholesterolemia. Arteriosclerosis: 545a, 1984

Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolemia. European Journal of Clinical Pharmacology 37(2): 199-204, 1989

Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia. Minerva Cardioangiologica 37(12): 509-515, 1989

Fenofibrate and colestipol effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolemia. European Journal of Clinical Pharmacology 30(2): 191-194, 1986

Effects of polydextrose on serum lipids, lipoproteins, and apolipoproteins in healthy subjects. Clinical Therapeutics 13(2): 254-258, 1991

Effects of simvastatin on plasma lipids and apolipoproteins in primary hypercholesterolemia. Gotto, A M Jr , Et Al (Ed ) Treatment Of Severe Hypercholesterolemia in The Prevention Of Coronary Heart Disease; 2nd International Symposium, Munich, West Germany, June 29-30, 1989 Ix+274p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 112-115, 1990

Effects of bezafibrate on lipoprotein lipids and b and a1 apolipoproteins in patients with primary hypercholesterolemia. Clinica Terapeutica 122(1): 17-23, 1987

Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia. La Clinica Terapeutica 122(1): 17-23, 1987

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism Clinical & Experimental 41(5): 498-503, 1992

Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia. Clinical Therapeutics 11(2): 247-257, 1989

Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Canadian Journal of Cardiology 7(1): 27-33, 1991

N-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. The American Journal of Clinical Nutrition 51(4): 599-605, 1990

n-3 fatty acid effects on lipids, lipoproteins, and apolipoproteins at very low doses: results of a randomized controlled trial in hypertriglyceridemic subjects. American Journal of Clinical Nutrition 51(4): 599-605, 1990

Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia. Atherosclerosis 53(3): 321-325, 1984

Effect of therapy on blood serum lipids and prolonged fenofibrate lipoproteins in patients with hypercholesterolemia and hypertriglyceridemia. Polski Tygodnik Lekarski 41(51-52): 1633-1637, 1986